Deals in Depth: September 2023
Executive Summary
Six $1bn+ alliances were penned in September. Topping the list was a potential $3.46bn multi-year deal between Nurix Therapeutics and Seagen to advance a new class of medicines called Degrader-Antibody Conjugates for use in cancer. The collaboration will focus on an innovative approach to combine two powerful technologies to target cancer – antibody-drug conjugation and targeted protein degradation – with the goal of creating drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.
You may also be interested in...
Deals In Depth: October 2023
Nine $1bn+ alliances were penned in October. Topping the list was a potential $22bn deal between Daiichi Sankyo and Merck for the global development and commercialization of Daiichi’s DXd antibody drug conjugate candidates patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.
Dealmaking Quarterly Statistics, Q3 2023
During Q3, biopharma merger and acquisition deal value reached $13.6bn and drew in $36.5bn in potential deal value from alliances. Device company M&A values reached $4.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $5.8bn.
Financing Quarterly Statistics, Q3 2023
During Q3, biopharmas brought in an aggregate $23.3bn in financing and device company fundraising totaled $3.6bn; while in vitro diagnostic firms and research tools players raised $649m.